The basal ganglia sit at the crossroads of motor control, reward, and habit formation. Yet for most medical students, they remain a confusing collection of structures with intimidating names. This article builds your understanding from anatomy to bedside — by the end, you should be able to explain a Parkinson's patient's tremor from first principles.
Anatomy — The Key Structures
The basal ganglia are a group of subcortical nuclei that work together as a motor control circuit. The main components:
| Structure | Location | Role |
|---|---|---|
| Caudate nucleus | C-shaped, borders lateral ventricle | Cognitive and associative functions; part of striatum |
| Putamen | Lateral to internal capsule | Motor control; part of striatum. Caudate + Putamen = Striatum |
| Globus Pallidus (GP) | Medial to putamen | GPi (internal) = main output nucleus; GPe (external) = relay |
| Subthalamic nucleus (STN) | Below thalamus, above substantia nigra | Excitatory modulator of GPi; target for DBS in Parkinson's |
| Substantia Nigra | Midbrain | SNc produces dopamine → striatum; SNr = output nucleus |
Striatum = Caudate + Putamen (they look striped on sections — hence the name). The lentiform nucleus = Putamen + Globus Pallidus. The corpus striatum = lentiform + caudate. These terms come up in radiology reports — know them.
The Circuit — Direct and Indirect Pathways
The basal ganglia work through two opposing pathways to regulate movement. Understanding these explains most movement disorders:
Direct Pathway — "Go" Signal
Cortex → Striatum → GPi/SNr (inhibited) → Thalamus (disinhibited) → Cortex → Movement facilitated. Dopamine from SNc acts on D1 receptors in striatum to facilitate this pathway. Result: movement is promoted.
Indirect Pathway — "Stop" Signal
Cortex → Striatum → GPe (inhibited) → STN (disinhibited) → GPi (excited) → Thalamus (inhibited) → Cortex → Movement suppressed. Dopamine acts on D2 receptors to inhibit this pathway. Result: movement is suppressed.
Dopamine facilitates movement — it promotes the direct pathway and inhibits the indirect pathway simultaneously. Loss of dopamine (Parkinson's) → overactive indirect pathway → excessive inhibition of thalamus → poverty of movement (bradykinesia). Excess dopamine (or dopamine agonists) → overactive direct pathway → excessive movement (dyskinesia, chorea).
Clinical Disorders of the Basal Ganglia
| Disorder | Pathology | Movement Pattern | Key Feature |
|---|---|---|---|
| Parkinson's Disease | Loss of dopaminergic neurons in SNc | Hypokinetic — bradykinesia, rigidity, resting tremor | Pill-rolling tremor 4–6Hz, asymmetric onset, L-DOPA responsive |
| Huntington's Disease | CAG repeat expansion — caudate atrophy | Hyperkinetic — chorea (random, flowing movements) | Autosomal dominant, dementia, psychiatric symptoms, caudate atrophy on MRI |
| Hemiballismus | Contralateral STN lesion (usually infarct) | Wild flinging movements of proximal limbs | Acute onset, ipsilateral to normal STN — contralateral STN lesion |
| Wilson's Disease | Copper deposition in putamen and liver | Tremor, dysarthria, dystonia | Kayser-Fleischer rings, young patient, liver disease, low caeruloplasmin |
Parkinson's Disease — A Closer Look
Parkinson's is the most important basal ganglia disorder clinically. It affects 1% of people over 60 and is the second most common neurodegenerative disease after Alzheimer's.
Clinical Features of Parkinson's Disease
- Bradykinesia — slowness of movement. Mandatory for diagnosis. Manifests as: micrographia (small handwriting), hypomimia (mask-like face), hypophonia (quiet voice), festinant gait (shuffling, small steps).
- Resting tremor — 4–6Hz, "pill-rolling" (thumb over fingers), suppressed by voluntary movement, worsened by distraction. Asymmetric at onset.
- Rigidity — "lead pipe" rigidity throughout range of movement. "Cogwheel" rigidity when tremor superimposed on rigidity. Test by passively rotating the wrist.
- Postural instability — late feature, causes falls. Positive "pull test" — patient cannot recover when pulled backward.
- Non-motor features — often predate motor symptoms by years: anosmia, REM sleep behaviour disorder, constipation, depression, autonomic dysfunction.
Treatment Principles
Levodopa (L-DOPA) remains the most effective treatment — it crosses the blood-brain barrier and is converted to dopamine in remaining SNc neurons. Given with carbidopa (a peripheral decarboxylase inhibitor) to prevent peripheral conversion and nausea.
Deep Brain Stimulation (DBS) of the subthalamic nucleus is the most important neurosurgical intervention in Parkinson's — high-frequency stimulation effectively inhibits the overactive STN, reducing GPi output and restoring thalamic activity. Dramatically improves motor fluctuations and dyskinesia in advanced disease.
DBS of the STN is one of the most successful neurosurgical procedures in movement disorders. The target — the subthalamic nucleus — is only 6mm in diameter, located deep in the brain. Intraoperative microelectrode recording identifies the characteristic high-frequency firing pattern of STN neurons. It is a remarkable example of understanding neural circuits translating directly into surgical cure.
Striatum = caudate + putamen. Direct pathway = "go" (dopamine promotes). Indirect pathway = "stop" (dopamine inhibits). Loss of dopamine = Parkinson's = bradykinesia + tremor + rigidity. Huntington's = CAG repeat + caudate atrophy + chorea. Hemiballismus = contralateral STN lesion. Wilson's = young patient + KF rings + liver disease. DBS of STN = key neurosurgical treatment for advanced Parkinson's.
References
- Postuma RB et al. MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders. 2015;30(12):1591–1601.
- Obeso JA et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders. 2017;32(9):1264–1310.
- Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends in Neurosciences. 1989;12(10):366–375.
